ARQT NASDAQ
Arcutis Biotherapeutics, Inc.
1W: -3.5%
1M: +15.9%
3M: +13.7%
YTD: +9.2%
1Y: +57.5%
3Y: +1182.6%
5Y: +44.1%
$31.68
-0.13 (-0.41%)
Weekly Expected Move ±9.8%
$25
$28
$31
$34
$37
Credit Risk of going bust: lower than 69% of companies Debt: 2.8% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the safest four tenths, about 1 in 3,500 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.11 (down 99.7%), Arcutis Biotherapeutics, Inc. would be worth roughly what it owes.
Total debt $114.1M against a stock market value of $3.98B.
Distance to default 7.37 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $57.9M (short-term plus half of long-term), stock volatility 56.8%; Altman Z'' -2.01. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
If the stock fell to about $0.11 (down 99.7%), Arcutis Biotherapeutics, Inc. would be worth roughly what it owes.
Total debt $114.1M against a stock market value of $3.98B.
Distance to default 7.37 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $57.9M (short-term plus half of long-term), stock volatility 56.8%; Altman Z'' -2.01. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
4 relationships4
As Filer
counterparties named
0
As Counterparty
mentioned by others
3
Rel. Types
2022-09-07
Earliest Filing
2024-02-28
Latest Filing
licensee: 2
partner: 1
target: 1
Counterparties (Filed by ARQT)
4 relationshipsCompanies named in ARQT's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| Sato Pharmaceutical Co., Ltd. | — | licensee | Arcutis granted Sato an exclusive license to develop, manufacture, and commercialize ZORYVE products in Japan. | 2024-02-28 | View |
| Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | — | licensee | Granted exclusive license for ZORYVE® and ARQ-154 in Greater China and Southeast Asia | 2023-08-14 | View |
| Huadong Medicine Co., Ltd. | — | partner | Parent company of Huadong, the licensee | 2023-08-14 | View |
| Ducentis Biotherapeutics LTD. | — | target | Acquired by Arcutis Biotherapeutics, Inc. for approximately $30 million upfront plus contingent payments. | 2022-09-07 | View |
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-08-05 | Earnings Release; Officer/Director Change; Exhibits | View | |
| 2026-07-16 | Officer/Director Change; Regulation FD; Exhibits | View | |
| 2026-06-09 | Shareholder Vote; Other Events; Exhibits | View | |
| 2026-05-06 | Exhibits | View | |
| 2026-02-25 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-12-08 | Departure/Election of Directors; Appointment of Officers; Regulation FD Disclosure; Financial Statem | View | |
| 2025-10-28 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-08-06 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-06-17 | Submission of Matters to a Vote of Security Holders; Other Events; Financial Statements and Exhibits | View | |
| 2025-05-06 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-04-10 | Departure/Election of Directors; Appointment of Officers; Regulation FD Disclosure; Financial Statem | View | |
| 2025-02-25 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-01-13 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2024-11-06 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2024-08-14 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2024-06-18 | Submission of Matters to a Vote of Security Holders | View | |
| 2024-05-14 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2024-04-10 | Departure/Election of Directors; Appointment of Officers; Regulation FD Disclosure; Financial Statem | View | |
| 2024-02-28 | Entry into Material Definitive Agreement | Agreement | View |
| 2024-02-27 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR